Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

NCT05114421 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

High Grade Fallopian Tube Serous Adenocarcinoma
High Grade Ovarian Serous Adenocarcinoma
Peritoneal High Grade Serous Adenocarcinoma
Recurrent High Grade Fallopian Tube Serous Adenocarcinoma
Recurrent High Grade Ovarian Serous Adenocarcinoma
Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma

Interventions

DRUG: Lenvatinib
BIOLOGICAL: Pembrolizumab

Sponsor

M.D. Anderson Cancer Center